Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects

NCT02474589 is registered in ClinicalTrials.gov with SIGA Technologies as lead sponsor.

NCT NCT02474589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02474589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects
Lead sponsor
SIGA Technologies
Phase
Phase 3
Overall status
Completed
Start date
June 19, 2015
Completion date
August 24, 2016
Enrollment
449 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

smallpox